



## **Cohere Medical Policy – Knee Arthroplasty**

*Clinical Guidelines for Medical Necessity Review*

**Version:** 6  
**Revision Date:** May 22, 2025

This policy was reviewed by the American Association of Orthopaedic Surgeons (AAOS) prior to publication.

# Important Notices

## Notices & Disclaimers:

**GUIDELINES SOLELY FOR COHERE'S USE IN PERFORMING MEDICAL NECESSITY REVIEWS AND ARE NOT INTENDED TO INFORM OR ALTER CLINICAL DECISION MAKING OF END USERS.**

Cohere Health, Inc. ("**Cohere**") has published these clinical guidelines to determine medical necessity of services (the "**Guidelines**") for informational purposes only, and solely for use by Cohere's authorized "**End Users**". These Guidelines (and any attachments or linked third party content) are not intended to be a substitute for medical advice, diagnosis, or treatment directed by an appropriately licensed healthcare professional. These Guidelines are not in any way intended to support clinical decision-making of any kind; their sole purpose and intended use is to summarize certain criteria Cohere may use when reviewing the medical necessity of any service requests submitted to Cohere by End Users. Always seek the advice of a qualified healthcare professional regarding any medical questions, treatment decisions, or other clinical guidance. The Guidelines, including any attachments or linked content, are subject to change at any time without notice.

©2025 Cohere Health, Inc. All Rights Reserved.

---

## Other Notices:

HCPCS® and CPT® copyright 2025 American Medical Association. All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

HCPCS and CPT are registered trademarks of the American Medical Association.

---

## Guideline Information:

**Specialty Area:** Disorders of the Musculoskeletal System

**Guideline Name:** Cohere Medical Policy - Knee Arthroplasty

**Date of last literature review:** 1/10/2025

**Document last updated:** 5/19/2025

**Type:**  Adult (18+ yo) |  Pediatric (0-17 yo)

## **Table of Contents**

<b>Important Notices</b>	<b>2</b>
<b>Medical Necessity Criteria</b>	<b>4</b>
<b>Service: Knee Arthroplasty</b>	<b>4</b>
Recommended Clinical Approach	4
Medical Necessity Criteria	5
Indications	5
Non-Indications	9
Level of Care Criteria	10
Procedure Codes (CPT/HCPCS)	10
<b>Medical Evidence</b>	<b>12</b>
<b>References</b>	<b>15</b>
<b>Clinical Guideline Revision History/Information</b>	<b>19</b>

# Medical Necessity Criteria

## ***Service: Knee Arthroplasty***

### **Recommended Clinical Approach**

Total knee arthroplasty (TKA) is the most commonly performed joint replacement procedure in the United States and is expected to increase in frequency in the coming years. During the operation, the damaged bone and cartilage are replaced with a metal and plastic-based prosthesis that can tolerate repetitive motion and wear as the patient ages. TKA can relieve pain, restore function, and improve a patient's quality of life. It may be performed on one or both knees. Opinions differ as to whether bilateral TKA should be performed simultaneously in the same operation, replacing both knees at once, or staged, wherein the knees are replaced during separate procedures. The majority of staged bilateral procedures occur between six months to a year apart.<sup>1-4</sup> Unicompartamental knee arthroplasty (UKA) is an alternative to TKA, which is used to partially replace the knee for individuals whose disease is limited to only one area. Patellofemoral arthroplasty is another type of partial knee arthroplasty, reserved for patients with isolated patellofemoral disease. During partial knee replacements, the healthy parts of the knee are retained, potentially resulting in more natural-feeling motion and function. Importantly, the primary risk of a partial knee replacement is the possibility of eventual total knee arthroplasty, should additional joint and cartilage disease develop in other areas of the knee in the future. Revision or repeat TKA is performed when an initial knee arthroplasty fails or has suboptimal results. This may occur when the components of the knee prosthesis loosen or break, or become infected. A prior TKA may also be revised when bone loss progresses around the prosthetic. In some cases, only a portion of the prosthesis will be replaced, while in others, the entire prosthesis must be removed and replaced, often with specialized implants that provide extra durability and support.<sup>5</sup>

## Medical Necessity Criteria

### Indications

→ A **knee arthroplasty** is considered appropriate if **ANY** of the following is **TRUE**:

- ◆ The procedure is a **primary total knee arthroplasty (TKA)** for advanced joint disease, and **ALL** of the following are **TRUE**<sup>4-6</sup>:
  - Imaging confirms **ANY** of the following<sup>7-8</sup>:
    - Joint space narrowing (less than 50%) and marginal osteophytes or subchondral sclerosis; **OR**
    - Joint space narrowing (greater than 50%); **OR**
    - Complete joint space loss; **OR**
    - Avascular necrosis; **OR**
    - Failed previous unicompartmental joint replacement;**AND**
  - Pain or functional disability<sup>4-8</sup>; **AND**
  - **ANY** of the following<sup>4-8</sup>:
    - Failure of conservative management for greater than 3 months, including **ALL** of the following:
      - ◆ Anti-inflammatory medications, non-opioid analgesics, or prescription medications (e.g., oral steroids, neuropathic pain medications) if not contraindicated; **AND**
      - ◆ Physical therapy or physician-directed exercise program; **AND**
      - ◆ **ANY** of the following:
        - Corticosteroid injection if medically appropriate; **OR**
        - Documentation that corticosteroid injection is contraindicated; **AND**
      - ◆ **ANY** of the following:
        - Weight reduction if BMI is greater than 40<sup>17,18</sup>; **OR**
        - Documentation of attempted weight loss or weight loss counseling if BMI is greater than 40<sup>17,18</sup>; **OR**
        - Weight loss not applicable (BMI less than 40)<sup>17,18</sup>; **OR**

- Documentation indicating that conservative, non-surgical management would be ineffective or counterproductive based on **ANY** of the following<sup>4-8</sup>:
  - ◆ Intractable pain or significant disabling interference with activities of daily living (ADLs); **OR**
  - ◆ Bone-on-bone articulation; **OR**
  - ◆ Severe deformity; **OR**
  - ◆ Failure of a previous osteotomy; **OR**
  - ◆ Distal femur fracture; **OR**
  - ◆ Malignancy of **ANY** of the following:
    - Distal femur; **OR**
    - Proximal tibia; **OR**
    - Knee joint or adjacent soft tissues; **OR**
  - ◆ Failure of previous unicompartmental knee replacement; **OR**
  - ◆ Avascular necrosis of the knee; **OR**
  - ◆ Proximal tibia fracture; **OR**
- ◆ The procedure is a **repeat or revision TKA**, and **ANY** of the following is **TRUE**<sup>14,19-27</sup>:
  - Loosening of one or more components; **OR**
  - Fracture or mechanical failure of one or more components; **OR**
  - Infection; **OR**
  - Treatment of periprosthetic fracture of distal femur, proximal tibia, or patella; **OR**
  - Progressive or substantial periprosthetic bone loss; **OR**
  - Bearing surface wear leading to symptomatic synovitis; **OR**
  - Implant or knee misalignment; **OR**
  - Knee stiffness (arthrofibrosis); **OR**
  - Tibiofemoral instability; **OR**
  - Extensor mechanism instability or disruption; **OR**
  - Dislocation of the knee joint; **OR**
- ◆ The procedure is a **unicompartmental knee arthroplasty** and **ANY** of the following is **TRUE**<sup>7-9</sup>:
  - Unicompartmental knee degenerative joint disease and **ALL** of the following are **TRUE**<sup>7</sup>:
    - Disabling pain and/or functional disability that limits ADLs; **AND**

- **ANY** of the following:
  - ◆ Failure of conservative management for greater than 3 months, including **ALL** of the following:
    - Anti-inflammatory medications, non-opioid analgesics, or prescription medications (e.g., oral steroids, neuropathic pain medications) if not contraindicated; **AND**
    - Physical therapy or physician-directed exercise program; **AND**
    - **ANY** of the following:
      - Corticosteroid injection if medically appropriate; **OR**
      - Documentation that corticosteroid injection is contraindicated; **AND**
    - **ANY** of the following:
      - Weight reduction if BMI is greater than 40<sup>L7.18</sup>; **OR**
      - Documentation of attempted weight loss or weight loss counseling if BMI is greater than 40<sup>L7.18</sup>; **OR**
      - Weight loss not applicable (BMI less than 40)<sup>L7.18</sup>; **OR**
  - ◆ Documentation indicating that conservative, non-surgical management would be ineffective or counterproductive based on **ANY** of the following<sup>4-8</sup>:
    - Intractable pain or significant disabling interference with activities of daily living (ADLs); **OR**
    - Bone-on-bone articulation in one compartment; **OR**
    - Severe deformity; **OR**
    - Failure of a previous osteotomy; **OR**
    - Malignancy of knee joint or adjacent soft tissues; **OR**
    - Avascular necrosis of the knee; **AND**

- Weight-bearing radiograph shows **ANY** of the following evidence of osteoarthritis in a single compartment of the knee:
  - ◆ Joint space narrowing (less than 50%) and marginal osteophytes or subchondral sclerosis; **OR**
  - ◆ Joint space narrowing (greater than 50%); **OR**
  - Unicompartamental osteonecrosis<sup>7-9</sup>; **OR**
  - Unicompartamental post-traumatic joint destruction<sup>7-9</sup>; **OR**
  - Partial resection of the knee needed for treatment of malignancy<sup>7-9</sup>; **OR**
- ◆ The procedure is a **patellofemoral arthroplasty** and **ANY** of the following is **TRUE**<sup>10-11</sup>:
  - Knee patellofemoral degenerative joint disease and **ALL** of the following are **TRUE**<sup>10-11</sup>:
    - Isolated pain in the front of the knee; **AND**
    - Disabling pain and/or functional disability limit ADLs; **AND**
    - **ANY** of the following:
      - ◆ Failure of conservative management for greater than 3 months, including **ALL** of the following:
        - Anti-inflammatory medications, non-opioid analgesics, or prescription medications (e.g., oral steroids, neuropathic pain medications) if not contraindicated; **AND**
        - Physical therapy or physician-directed exercise program; **AND**
        - **ANY** of the following:
          - Corticosteroid injection if medically appropriate; **OR**
          - Documentation that corticosteroid injection is contraindicated; **AND**
        - **ANY** of the following:
          - Weight reduction if BMI is greater than 40<sup>17,18</sup>; **OR**
          - Documentation of attempted weight loss or weight loss

- counseling if BMI is greater than 40<sup>17,18</sup>; **OR**
- Weight loss not applicable (BMI less than 40)<sup>17,18</sup>; **OR**
- ◆ Documentation indicating that conservative, non-surgical management would be ineffective or counterproductive based on **ANY** of the following<sup>4-8</sup>:
  - Intractable pain or significant disabling interference with activities of daily living (ADLs); **OR**
  - Bone-on-bone articulation in the patellofemoral compartment; **OR**
  - Severe deformity; **OR**
  - Failure of a previous osteotomy; **OR**
  - Malignancy of knee joint or adjacent soft tissues; **AND**
- Weight-bearing radiograph and Merchant view show **ANY** of the following evidence of osteoarthritis in the patellofemoral compartment:
  - ◆ Joint space narrowing (less than 50%) and marginal osteophytes or subchondral sclerosis; **OR**
  - ◆ Joint space narrowing (greater than 50%); **OR**
  - ◆ Complete joint space loss; **OR**
- Patellofemoral post-traumatic destruction (e.g., history of patella fracture)<sup>10-11</sup>; **OR**
- Dysplasia of the trochlea.<sup>10-11</sup>

## Non-Indications

→ A **knee arthroplasty** is not considered appropriate if **ANY** of the following is **TRUE**<sup>1-12</sup>:

- ◆ Skeletal immaturity; **OR**
- ◆ Active infection of the knee joint or active systemic bacteremia; **OR**
- ◆ Active urinary tract or dental infection; **OR**
- ◆ Active skin infection (except recurrent cutaneous staph infections) or open wound within the planned surgical site of the knee; **OR**

- ◆ Rapidly progressive neurological disease; **OR**
- ◆ Any process that is rapidly destroying bone; **OR**
- ◆ Neurotrophic arthritis; **OR**
- ◆ If the procedure is a unicompartmental knee arthroplasty and **ANY** of the following is **TRUE**:
  - Severe patellofemoral osteoarthritis <sup>12</sup>; **OR**
  - Flexion contracture greater than 10 degrees<sup>13</sup>; **OR**
  - More than 10 degrees of fixed varus or valgus without plan to address; **OR**
  - Diagnosis of inflammatory arthritis<sup>12</sup>; **OR**
  - Ligamentous instability without plan to address; **OR**
- ◆ If the procedure is a patellofemoral knee arthroplasty and **ANY** of the following is **TRUE**<sup>11</sup>:
  - Radiographic evidence of tibiofemoral osteoarthritis; **OR**
  - Fixed flexion contracture greater than 10 degrees; **OR**
  - Uncorrected patellofemoral malalignment or instability; **OR**
  - Diagnosis of inflammatory arthritis.

**Level of Care Criteria**

Inpatient or Outpatient

**Procedure Codes (CPT/HCPCS)**

CPT/HCPCS Code	Code Description
27437	Arthroplasty, patella; without prosthesis
27438	Arthroplasty, patella; with prosthesis
27440	Arthroplasty, knee, tibial plateau
27441	Arthroplasty, knee, tibial plateau; with debridement and partial synovectomy
27442	Arthroplasty, femoral condyles or tibial plateau(s), knee
27443	Arthroplasty, femoral condyles or tibial plateau(s), knee; with debridement and partial synovectomy
27445	Arthroplasty, knee, hinge prosthesis (e.g., Walldius

	type)
27446	Arthroplasty, knee, condyle and plateau; medial OR lateral compartment
27447	Arthroplasty, knee, condyle and plateau; medial AND lateral compartments with or without patella resurfacing (total knee arthroplasty)
27486	Revision of total knee arthroplasty, with or without allograft; 1 component
27487	Revision of total knee arthroplasty, with or without allograft; femoral and entire tibial component
27488	Removal of prosthesis, including total knee prosthesis, methylmethacrylate with or without insertion of spacer, knee
27599	Unlisted procedure, femur or knee

## Medical Evidence

Bin et al. (2023) performed a meta-analysis of 17 randomized controlled trials (RCTs) to compare surgical interventions for knee osteoarthritis, including total knee arthroplasty (TKA), unicompartmental knee arthroplasty (UKA), high tibial osteotomy (HTO), bicompartamental knee arthroplasty (BCA), bi-unicompartmental knee arthroplasty (BIU), and knee joint distraction (KJD). The authors analyzed 21 studies (including 17 RCTs) on surgical complications, revisions, reoperations, and functional outcomes. Overall, TKA and UKA offered the best outcomes in the treatment of osteoarthritis.<sup>14</sup>

Papakostidis et al. (2021) analyzed serious adverse events (SAEs) following TKA. The authors noted a reduction in SAEs over the last decade, specifically emphasizing the decrease in surgical complications, venous thromboembolism (VTE) events, and infections. These improvements have resulted from stricter protocols for VTE prevention, patient decolonization procedures, surgical air quality optimization, preoperative cardiac clearance, diabetic control, and participation in weight reduction programs.<sup>15</sup>

Shichman et al. (2023) analyzed data from the Centers for Medicare & Medicaid Services (CMS) Medicare/Medicaid Part B National Summary and the number of procedures based on Current Procedural Terminology (CPT) codes. The codes were separated into primary total hip arthroplasty (THA) or total knee arthroplasty (TKA). A total of 480,958 primary TKA were performed in 2019. The values were a baseline for producing point forecasts for procedures expected to be performed between 2020–2060 and 95% forecast intervals (FIs). From 2000 to 2019, TKA increased annually by 156%. Regression analysis predicts annual growth rates of 4.44% for TKA – an expected increase of 24.28% for TKA every five years post-2020. By 2040, TKAs are expected to be 1,222,988. That number will increase to 2,917,959 for TKAs by 2060. The authors note that by 2040, the number of TKAs is projected to rise by 139% by 2040 and 469% by 2060. Accurately projecting future arthroplasty needs is crucial for understanding future healthcare utilization and surgeon demand. The findings are specific to the Medicare population; additional analysis is required to determine if other groups apply.<sup>16</sup>

Unicompartmental knee arthroplasty has been traditionally considered for elderly patients because of its relatively shorter rehabilitation period, smaller incision, and preservation of range of motion and function. However, a large study of 11-year knee survivorship among patients less than 60 years old found a 92% rate of survivorship; a similar study of elderly patients undergoing cemented UKA found a 10-year survivorship of 98%.<sup>5</sup> Patellofemoral arthroplasty necessitates careful patient selection, as evidenced by risk of subsequent revision to TKA – most commonly resultant from progressive tibiofemoral arthritis. The current body of research also suggests a higher rate of revision to TKA among obese patients, with knee survivorship and rate of satisfactory results generally lower than primary TKA.<sup>5</sup> Revision rates of knee arthroplasty are low, as most primary implants are both well-tolerated and durable. As the field has evolved, the most common etiologies prompting revision are now infection and instability, rather than bone destruction or mechanical loosening. Clinical outcomes of revision TKA are less favorable than primary TKA, and 5-year follow-up satisfaction rates have been reported up to 74%, versus primary TKA satisfaction approaching 100%.<sup>5</sup>

The American Academy of Orthopaedic Surgeons (AAOS) has issued position statements pertaining to knee arthroplasty. Information statement 1047, published in 2016, acknowledges the increased patient safety risks conferred by tobacco use – including pneumonia, impeded healing, surgical site infection, postoperative cardiopulmonary events, and death.<sup>39</sup> The AAOS states that patients who are active smokers may reduce these risks through cessation of smoking prior to surgery; they also note the special role orthopaedic surgeons play in counseling patients on the benefits of reduced or eliminated tobacco use prior to surgery.<sup>39</sup> Importantly, unconfirmed cessation is not endorsed as a hard stop to surgery; rather, the surgeon's unique role as an advocate for preoperative smoking cessation is emphasized.<sup>39</sup> Statements 1040 and 1184 discuss the impact of obesity on musculoskeletal conditions.<sup>17,18</sup> Statement 1184 endorses the importance of continued patient–surgeon conversation around the increased surgical risks associated with obesity, including increased complications and rates of hardware failure following knee replacement. Patients with morbid obesity (BMI of 40 or above) are encouraged to participate in a weight loss program, obtain weight reduction resources through their physician, rectify nutritional deficiencies, and consider a delay in surgical treatment if it would facilitate

participation in weight loss interventions that may improve surgical outcomes. Statement 1040 reinforces the risks associated with obesity and total joint arthroplasty and encourages adequate patient counseling prior to surgery.<sup>17,18</sup> Social determinants of health remain an important area of ongoing orthopaedic surgery research, with recent literature raising questions regarding the healthcare disparities that may be potentiated by care limitations based on obesity and smoking status/nicotine dependence.<sup>29-31,35-38</sup> Other ongoing research interrogates the impacts that biological sex, race, and socioeconomic status have on TKA utilization and outcomes.<sup>32-34</sup>

## References

1. Gabr A, Withers D, Pope J, et al. Functional outcome of staged bilateral knee replacements. *Ann R Coll Surg Engl*. 2011 Oct;93(7):537–41. doi: 10.1308/147870811X13137608454803. PMID: 22004637.
2. Liu L, Liu H, Zhang H, et al. Bilateral total knee arthroplasty: Simultaneous or staged? A systematic review and meta-analysis. *Medicine (Baltimore)*. 2019 May;98(22):e15931. doi: 10.1097/MD.00000000000015931. PMID: 31145362; PMCID: PMC6708906.
3. Bohm ER, Molodianovitch K, Dragan A, et al. Outcomes of unilateral and bilateral total knee arthroplasty in 238,373 patients. *Acta Orthop*. 2016 Jul;87 Suppl 1(Suppl 1):24–30. doi: 10.1080/17453674.2016.1181817. PMID: 27167849; PMCID: PMC4937774.
4. Makaram NS, Roberts SB, Macpherson GJ. Simultaneous bilateral total knee arthroplasty is associated with shorter length of stay but increased mortality compared with staged bilateral total knee arthroplasty: a systematic review and meta-analysis. *J Arthroplasty*. 2021 Jun 1;36(6):2227–38. <https://doi.org/10.1016/j.arth.2021.01.045>
5. Mihalko WM. Arthroplasty of the knee. In: Azar FM, Beaty JH, editors. *Campbell's Operative Orthopaedics*. 14th ed. Philadelphia, PA: Elsevier; 2021:406–484.e12.
6. Gress K, Charipova K, An D, et al. Treatment recommendations for chronic knee osteoarthritis. *Best Pract Res Clin Anaesthesiol*. 2020 Sep;34(3):369–382. doi: 10.1016/j.bpa.2020.06.006. PMID: 33004154.
7. American Academy of Orthopaedic Surgeons (AAOS). Surgical management of osteoarthritis of the knee. Published December 2, 2022. Accessed December 3, 2024. <https://www.aaos.org/globalassets/quality-and-practice-resources/surgical-management-knee/smoak2cpg.pdf>.
8. Katz JN, Arant KR, Loeser RF. Diagnosis and treatment of hip and knee osteoarthritis: A review. *JAMA*. 2021 Feb 9;325(6):568–578. doi: 10.1001/jama.2020.22171. PMID: 33560326; PMCID: PMC8225295.
9. Chalmers BP, Mehrotra KG, Sierra RJ, et al. Reliable outcomes and survivorship of unicompartmental knee arthroplasty for isolated compartment osteonecrosis. *Bone Joint J*. 2018 Apr 1;100-B(4):450–454. doi: 10.1302/0301-620X.100B4.BJJ-2017-1041.R2. PMID: 29629588.

10. Ennis HE, Phillips JL, Jennings JM, et al. Patellofemoral arthroplasty. *J Am Acad Orthop Surg*. 2023 Oct 1;31(19):1009-1017. doi: 10.5435/JAAOS-D-23-00022. PMID: 37364255.
11. Cuthbert R, Tibrewal S, Tibrewal SB. Patellofemoral arthroplasty: Current concepts. *J Clin Orthop Trauma*. 2018 Jan-Mar;9(1):24-28. doi: 10.1016/j.jcot.2017.11.006. PMID: 29628679; PMCID: PMC5884050.
12. Borus T, Thornhill T. Unicompartmental knee arthroplasty. *J Am Acad Orthop Surg*. 2008 Jan;16(1):9-18. doi: 10.5435/00124635-200801000-00003. PMID: 18180388.
13. Kozinn SC, Scott R. Unicondylar knee arthroplasty. *J Bone Joint Surg Am*. 1989 Jan;71(1):145-50. PMID: 2643607.
14. Bin G, Jinmin L, Cong T, et al. Surgical interventions for symptomatic knee osteoarthritis: A network meta-analysis of randomized controlled trials. *BMC Musculoskelet Disord*. 2023 Apr 22;24(1):313. doi: 10.1186/s12891-023-06403-z. PMID: 37087428; PMCID: PMC10122318.
15. Papakostidis C, Giannoudis PV, Watson JT, et al. Serious adverse events and 30-day hospital readmission rate following elective total knee arthroplasty: A systematic review and meta-analysis. *J Orthop Surg Res*. 2021 Mar 31;16(1):236. doi: 10.1186/s13018-021-02358-w. PMID: 33789702; PMCID: PMC8011390.
16. Shichman I, Roof M, Askew N, et al. Projections and epidemiology of primary hip and knee arthroplasty in Medicare patients to 2040-2060. *JB JS Open Access*. 2023 Feb 28;8(1):e22.00112. doi: 10.2106/JBJS.OA.22.00112. PMID: 36864906; PMCID: PMC9974080.
17. American Academy of Orthopaedic Surgeons. Information Statement 1040: Obesity and Musculoskeletal Care. Published June 2022. Accessed January 3, 2025. <https://www.aaos.org/globalassets/about/bylaws-library/information-statements/1040-obesity-and-musculoskeletal-care.pdf>.
18. American Academy of Orthopaedic Surgeons. Information Statement 1184: The Impact of Obesity on Bone and Joint Health. Published March 2015. Accessed January 3, 2025. <https://www.aaos.org/contentassets/1cd7f41417ec4dd4b5c4c48532183b96/1184-the-impact-of-obesity-on-bone-and-joint-health1.pdf>.
19. Arapovic AE, Zalikha AK, Zamzam M, et al. Frailty Among Revision Total Knee Arthroplasty Recipients: Epidemiology and Propensity Score-weighted Analysis of Effect on In-hospital Postoperative Outcomes. *JAAOS*. 2024 Apr 15;32(8):e387-95.

20. Boelch SP, Jakuscheit A, Doerries S, et al. Periprosthetic infection is the major indication for TKA revision—experiences from a university referral arthroplasty center. *BMC MSK Disorders*. 2018 Dec;19:1–6.
21. Postler A, Lützner C, Beyer F, Tille E, Lützner J. Analysis of total knee arthroplasty revision causes. *BMC MSK Disorders*. 2018 Dec;19:1–6.
22. Tay ML, McGlashan SR, Monk AP, Young SW. Revision indications for medial unicompartmental knee arthroplasty: a systematic review. *Arch Ortho Trauma Surg*. 2022 Feb 1:1–4.
23. van Rensch PJ, Hannink G, Heesterbeek PJ, Wymenga AB, van Hellemond GG. Long-term outcome following revision total knee arthroplasty is associated with indication for revision. *J Arthroplasty*. 2020 Jun 1;35(6):1671–7.
24. Abram SG, Sabah SA, Alvand A, Price AJ. Differences in mortality and complication rates following revision knee arthroplasty performed for urgent versus elective indications. *BJJ*. 2021 Oct 1;103(10):1578–85.
25. Clement ND, Avery P, Mason J, Baker PN, Deehan DJ. First-time revision knee arthroplasty using a hinged prosthesis: Temporal trends, indications, and risk factors associated with re-revision using data from the national joint registry for 3,855 patients. *BJJ*. 2023 Jan 1;105(1):47–55.
26. Khan M, Osman K, Green G, Haddad FS. The epidemiology of failure in total knee arthroplasty: avoiding your next revision. *BJJ*. 2016 Jan 1;98(1\_Supple\_A):105–12.
27. Schwartz AM, Farley KX, Guild GN, Bradbury Jr TL. Projections and epidemiology of revision hip and knee arthroplasty in the United States to 2030. *J Arthroplasty*. 2020 Jun 1;35(6):S79–85.
28. Telang S, Yoshida B, Burdick GB, et al. Body Mass Index and the Risk of Postoperative Complications After Total Knee Arthroplasty. *JAAOS*. 2022 May 13:10–5435.
29. Sabesan VJ, Rankin KA, Nelson C. Movement is life—optimizing patient access to total joint arthroplasty: Obesity disparities. *JAAOS*. 2022 Nov 1;30(21):1028–35.
30. O'connor MI, Burney III D, Jones LC. Movement Is Life—Optimizing Patient Access to Total Joint Arthroplasty: Smoking Cessation Disparities. *JAAOS*. 2022 Nov 15;30(22):1055–8.
31. Connors JP, Strecker S, Nagarkatti D, Carangelo RJ, Witmer D. Increasing Body Mass Index Not Associated With Worse Patient-Reported Outcomes After Primary THA or TKA. *JAAOS*. 2022 May 13:10–5435.

32. Woolley KA, Chi H, Allahabadi S, et al. Sex-based differences in the utilization of shoulder, hip, and knee arthroplasty. *JAAOS Global Research & Reviews*. 2023 Aug 1;7(8):e23.
33. Rahman TM, Hennekes M, Mehaidli A, Shaw JH, Silverton CD. Marital status, race, insurance type, and socioeconomic status—assessment of social predictors for outcomes after total knee arthroplasty. *JAAOS*. 2022 May 13;10-5435.
34. Zalikha AK, Almsaddi T, Nham F, Hussein IH, El-Othmani MM. Comorbidity, Racial, and Socioeconomic Disparities in Total Knee and Hip Arthroplasty at High Versus Low-Volume Centers. *JAAOS*. 2023 Mar 1;31(5):e264-70.
35. Siddiqi A, Warren JA, McLaughlin J, et al. Demographic, comorbidity, and episode-of-care differences in primary total knee arthroplasty. *JBJS*. 2021 Feb 3;103(3):227-34.
36. Hamilton WG. No Smoking Allowed: Is the Operating Room the Next Place That Smoking Patients Undergoing Total Joint Arthroplasty Will Be Banned?: Commentary on an article by Eric H. Tischler, BA, et al.: "Smoking Increases the Rate of Reoperation for Infection within 90 Days After Primary Total Joint Arthroplasty". *JBJS*. 2017 Feb 15;99(4):e17.
37. Uvodich ME, Dugdale EM, Pagnano MW, et al. Outcomes of obese patients undergoing primary total knee arthroplasty: Trends over 30 years. *JBJS*. 2021 Feb 26;10-2106.
38. Muthusamy N, Singh V, Sicut CS, Rozell JC, Lajam CM, Schwarzkopf R. Trends of obesity rates between patients undergoing primary total knee arthroplasty and the general population from 2013 to 2020. *JBJS*. 2022 Mar 16;104(6):537-43.
39. American Academy of Orthopaedic Surgeons. Information Statement 1047: Tobacco Use and Orthopaedic Surgery. Published February 2016. Accessed January 3, 2025. <https://www.aaos.org/globalassets/about/bylaws-library/information-statements/1047-tobacco-use-and-orthopaedic-surgery-3.pdf>.

# Clinical Guideline Revision History/Information

Original Date: December 9, 2020		
Review History		
Version 2	10/23/2023	
Version 3	11/17/2023	
Version 4	9/20/2024	<ul style="list-style-type: none"> <li>● Updated language regarding conservative treatment.</li> </ul>
Version 5	2/20/2025	<p>Annual policy review and restructure:</p> <ul style="list-style-type: none"> <li>● Updated recommended clinical approach to the current format.</li> <li>● Added descriptions of UKA, patellofemoral arthroplasty, and revision TKA to recommended clinical approach and medical evidence sections.</li> <li>● Medical evidence section and references updated to reflect the current literature.</li> <li>● Replaced reference 4 with a more relevant, recent reference.</li> <li>● Changed “initial TKA” to “primary TKA”.</li> <li>● Added weight loss counseling as an option (in addition to documented attempted weight loss) for patients with BMI above 40.</li> <li>● Wordsmithed indications for clarity.</li> <li>● Removed non-indication of “insufficiency of extensor mechanism/quadriceps” as it is not an absolute contraindication.</li> <li>● Removed “joint subluxation” indication per MD feedback.</li> <li>● Loosened description of patellofemoral osteoarthritis to better reflect clinical presentation.</li> <li>● Added non-indication: “ligamentous instability without plan to address” per MD feedback.</li> </ul>

		<ul style="list-style-type: none"> <li>• Updated conservative care to current internal standard language and provided avenue for approval of UKA/PFA for scenario wherein conservative care is inappropriate or harmful.</li> <li>• Conservative care language modified to reflect non-opioid pain control.</li> <li>• Modified steroid injection language for clarity.</li> </ul>
Version 6	5/22/2025	<p>Added CPT code: 27488. No associated criteria change.</p> <p>Removal of “disabling pain, functional disability” as revision indications due to concern for inappropriate approval.</p>